- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07324031
[Studio sul dispositivo che non è approvato o autorizzato dalla FDA degli Stati Uniti] (ALARION EV)
[Studio del dispositivo non approvato o autorizzato dalla FDA statunitense]
The ALARION EV Study is a prospective, multi-center, single-arm, non-randomized study without concurrent or historical controls. The purpose of this pivotal study is to generate evidence of safety and effectiveness to apply for regulatory approvals for commercialization of the Parasternal EV-ICD System.
The objective of the study is to demonstrate safety and effectiveness of the Parasternal EV-ICD System through 6-months.
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
The primary safety endpoint is Freedom from Major Adverse Device Effects (MADEs) through 6 months. The primary effectiveness endpoint is Defibrillation Performance: Successful induced ventricular arrhythmia (IVA) test in the final system configuration.
Up to 40 Investigational Sites Worldwide will participate with up to 280 subjects enrolled in the study. At least 50% of subjects will be enrolled at sites in the United States.
Subjects meeting indications for ICD therapy who do not require permanent bradycardia pacing will be eligible for participation. Eligible Subjects will receive an Atala™ lead connected to an EV-ICD Pulse Generator positioned in a left pectoral or left lateral location. The Parasternal EV-ICD System will be tested to verify appropriate sensing and defibrillation.
Starting at 6 months, Subjects will be followed every 6 months until the study is closed. The study is expected to be ongoing for a minimum of 2.5 years from the date of first enrollment. Endpoints will be analyzed and summarized in a final study report after all active Subjects have completed the 6-month visit.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Sarah Hase, BS, CCRA
- Numero di telefono: +1 949-545-9820
- Email: sarah@atacor.com
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- At least 18 years old
- Class I or IIa indication for implantation of an ICD according to the ACC/AHA/HRS Guidelines or ESC guidelines
Exclusion Criteria:
- Patients who cannot read or write
- Expected survival < 1 year
- Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period
- Participation in any concurrent clinical study without prior approval from the Sponsor
- Inability or unwillingness to provide informed consent to participate in the study
- Any known circumstances which may prevent the completion of protocol testing and data collection through the 6-month follow-up visit
- Circumstances that may prevent data collection or completion of specified follow-up visits
- Allergies to any device materials listed in the Instructions for Use (IFU)
- Contraindication for temporary suspension of oral/systemic anticoagulation
Known history of lung disease with FEV1 < 1.0 Liter
Device Related:
- Implanted with or planned implantation of any device which delivers current in the body that may interfere with therapy delivery, including, but not limited to a pacemaker, LVAD or neurostimulator
- Implanted with a subcutaneous ICD lead, subcutaneous coils/arrays, epicardial patches or epicardial pace/sense leads
Any known need for MRI prior to approval of MRI conditional labeling
Anatomy Related:
- Known structural abnormalities of the heart that may increase risk of the Parasternal EV-ICD System procedure
- Known obstructed or restricted pathway into the mediastinum for the Atala™ lead
- Prior surgery with disruption of the lung, pericardium or connective tissue between the sternum and pericardium, including sternotomy of any type
- Known significant anatomic derangement of or within the thorax (e.g., pectus excavatum, significant scoliosis)
- History of thoracic radiation therapy or other medical treatments/conditions which may complicate the Parasternal EV-ICD System implant procedure
- Known adhesions in the thorax or history of medical treatments, surgeries or conditions that increase the potential for adhesions in the thorax
Surgically corrected congenital heart disease (not including catheter-based procedures)
Cardiac Related:
- Indication for permanent bradycardia pacing or cardiac resynchronization therapy
- Decompensated heart failure
- Currently on inotropic therapy
- Known history of pericardial disease, pericarditis or mediastinitis
Risk factors associated with defibrillation testing:
- Severe aortic stenosis
- Current Intracardiac LA or LV thrombus
- Severe proximal three-vessel or left main coronary artery disease without revascularization
- Hemodynamic instability
- Unstable angina
- Recent stroke or transient ischemic attack (within the last 3 months)
- Known inadequate external defibrillation
- LVEF < 20% (most recent assessment; must be within 180 days of consent)
- LVEDD >70 mm (most recent assessment; must be within 180 days of consent)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Parasternal EV-ICD System
Subjects implanted with the Atala™ lead and EV-ICD pulse generator
|
Subjects will receive the Atala™ lead and EV-ICD pulse generator being evaluated in the study.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Freedom from MADEs
Lasso di tempo: Through 6 months post-implant
|
Freedom from Major Adverse Device Effects (MADEs)
|
Through 6 months post-implant
|
|
Successful IVA Test
Lasso di tempo: At the time of procedure and up to 60 days post-implant
|
Successful induced ventricular arrhythmia (IVA) test in the final system configuration
|
At the time of procedure and up to 60 days post-implant
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- DOC-10325
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Atala™ lead and EV-ICD Pulse Generator
-
AtaCor Medical, Inc.Attivo, non reclutanteFibrillazione ventricolare | Tachicardia ventricolare | Aritmia ventricolareNuova Zelanda, Paraguay, Croazia